NASDAQ: TWST

Twist Bioscience (TWST) Stock Analysis & Forecast

Nov 13 close

$111.60−2.62 (−2.3%)

Gekko Brief

AI summaryNov 9 close

Twist Bioscience shares fell this week after a report from The Bear Cave, owned by Hunterbrook Media, argued the company's valuation looks inflated relative to its fundamentals and rivals. Alongside this, routine insider filings surfaced, including non-discretionary sell-to-cover transactions by President and COO Patrick John Finn and Chief Accounting Officer Robert F. Werner, tied to tax withholding on vesting restricted stock units, plus a Form 144 notice of intent to sell restricted securities. The company also confirmed that CEO Emily M. Leproust and CFO Adam Laponis will appear at the Jefferies Global Healthcare Conference on November 17 and the Evercore Healthcare Conference on December 1.

Shares closed at $135.34, down 12% in the latest session, sitting below the 50-day average of $151.23 but above the 200-day average of $91.68. The GekkoIndex reads 63.5, placing the stock in the Accumulation zone. Price sits 14.4% below Gekko Fair Value of $158.11.

Twist Bioscience reports fiscal results on 12 November 2026, before the open, just two days away and inside a typical 20-trading-day holding window; its last quarter showed revenue of $118.4 million, up 23% year over year, with an 8.6% reaction. No insider, Congress, or unusual options activity appears in their respective 90-day and 30-day windows. Seasonality over the past 5 years shows the next 20 trading days averaging +2.3%, with gains in 3 of those years, worth noting alongside the earnings date.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Twist Bioscience price vs fair value

$131.34$111.60Nov ’25May ’26Nov ’26
Close $111.60200-day averageGekko Fair Value $131.34

Twist Bioscience quick facts

Market cap
$7.35B
P/E ratio
—
Forward P/E
—
EPS, TTM
−$2.23
Revenue, TTM
$431.8M
Profit margin
-31.7%
Dividend yield
—
Beta
2.22
Volume
2.05M avg 2.41M
1-year return
+250.2%
Typical daily move
±16.5%
Typical 20-day move
±15.1%
50-day average
$150.22
200-day average
$93.24
Next earnings
Feb 1 before open
Shares outstanding
66.30M
52-week range
$23.30$219.71

Twist Bioscience swing-trade checklist

Twist Bioscience scores 5 supportive, 1 mixed and 0 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

5 supportive1 mixed0 headwinds

  • Trendmixed

    Averages disagree

    Close $111.60 sits between the 50-day ($150.22) and 200-day ($93.24) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    69.1, Accumulation

    Reading 69.1 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    15.0% below

    Price is 15% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 30 days: 1 unusual options signal.

    See smart money
  • Earnings risksupportive

    Reports in 78 days

    Next report Feb 1, 2027, 78 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +6.3% on average

    From this point in the calendar, the next 20 trading days averaged +6.3% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Twist Bioscience stock chart and price history

Twist Bioscience closed at $111.60 on Nov 13, 2026, +250.2% over the past year, inside a 52-week range of $23.30 to $219.71.

Close50-day average200-day averageVolume
Twist Bioscience share price, past year, with 50-day and 200-day moving averages and volume$50$150$200DecJan 2026FebMarAprMayJunJulAugSepOctNov111.60

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−22.8%
3 months
−10.3%
6 months
+127.0%
1 year
+250.2%
The full TWST chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open TWST in Gekko

Follow Twist Bioscience through every session

Put TWST on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track TWST in GekkoFree for 7 days. No credit card required.

About Twist Bioscience

Twist Bioscience makes synthetic DNA and related products for research and biotechnology customers. Its manufacturing approach writes artificial DNA strands directly onto silicon chips, and it is known for this chip-based synthesis method. From this platform it produces custom genes, tools for preparing genetic samples, antibody libraries used in drug research, and methods for storing digital data in DNA.

The company works with outside partners rather than only selling standalone products. It has collaborations with organizations such as Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, deepCDR Biologics AG, and Centogene N.V., aimed at developing sequencing technology. It also has a research partnership with Boehringer Ingelheim, supplying its antibody libraries so the two can search for and develop antibody-based therapies against a range of biological targets.

Twist Bioscience was founded in 2013 and is based in South San Francisco, California. Its shares are listed on the NASDAQ under the ticker TWST.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
twistbioscience.com

Twist Bioscience GekkoIndex: the smart money zone

Twist Bioscience’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 69.1, in the Accumulation zone, up 2.8 points over five sessions.

010069.1Accumulation

Up 2.8 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying29+4.8%+8.2%+15.9%+22.9%
Accumulation (current zone)214+1.4%+3.0%+6.6%+12.3%
Neutral397+1.3%+2.9%+5.7%+15.4%
Distribution61+1.2%+2.3%+1.3%+27.8%
Selling1Too few readings yet

Average TWST share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the TWST price, zone by zone.Track TWST in Gekko

Is Twist Bioscience stock overvalued? Gekko Fair Value

Twist Bioscience trades 15.0% below Gekko Fair Value of $131.34, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Twist Bioscience shares are worth, recalculated every trading day.

$131.34

Gekko Fair Value, Nov 14, 2026

15.0% Undervalued

At the end of Aug 2026 the price was 30.9% above the estimate.

Gekko Fair ValueShare price, month end
$131$112Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open TWST in Gekko

Twist Bioscience insider and Congress trading

No open-market insider purchases were filed for Twist Bioscience, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for TWST in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every TWST insider filing, plotted on the chart in Gekko.Open TWST in Gekko

Congress trades last 90 days

No trades in TWST were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for TWST, plotted on the chart in Gekko.Open TWST in Gekko

Buybacks

Twist Bioscience has been buying back its own shares.

Bought back, quarter ended Jun 30, 2026
$6K
As a share of market cap
0.00%
Trailing four quarters
$18K

From company filings.

Unusual options activity last 30 days

1signal, 100% of the flagged premium in calls.

Latest: Bullish flow on Nov 10, $1.37M in unusual premium.

Hedge funds and billionaires quarter ended Jun 30

0of the funds Gekko tracks hold TWST.

0added0opened0trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

Twist Bioscience earnings: next date and track record

Twist Bioscience reports on Feb 1, 2027, before the open (78 days away), and beat the EPS estimate in 4 of its last 8 reports.

4 of 8reports beat the EPS estimate
±10.4%average move across the report
2 of 8reports followed by a gain

Share-price move across each report

−0.7%Feb ’25−16.5%May ’25−18.3%Aug ’25−11.5%Nov ’25+12.8%Feb ’26−6.1%May ’26+8.6%Aug ’26−9.0%Nov ’26
ReportedEPSSurpriseRevenueSurpriseMove
Nov 12, 2026−$0.32
est −$0.39
+17.3%$126.6M
est $123.5M
+2.5%−9.0%
Aug 3, 2026−$0.56
est −$0.50
−12.0%$118.4M
est $114.5M
+3.4%+8.6%
May 4, 2026−$0.71
est −$0.48
−47.9%$110.7M
est $107.6M
+2.9%−6.1%
Feb 2, 2026−$0.50
est −$0.48
−4.2%$103.7M
est $101.9M
+1.8%+12.8%
Nov 14, 2025−$0.45
est −$0.50
+10.0%$99.01M
est $97.40M
+1.7%−11.5%
Aug 4, 2025−$0.47
est −$0.54
+13.0%$96.06M
est $97.38M
−1.4%−18.3%
May 5, 2025−$0.66
est −$0.56
−17.9%$92.79M
est $95.39M
−2.7%−16.5%
Feb 3, 2025−$0.53
est −$0.63
+15.9%$88.71M
est $86.95M
+2.0%−0.7%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Twist Bioscience stock forecast and analyst price targets

Analysts’ average 12-month price target for Twist Bioscience is $168.25, +50.8% from the last close, from 9 firms rating the stock in the last 90 days.

$168.25consensus 12-month target, +50.8% from the last close
Low $45High $215
Buy6
Hold2
Sell1

Each firm’s latest rating in the last 90 days: 9 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13TD CowenBuy, reiterated$137+22.8%
Nov 13Robert W. BairdBuy, maintained$135+21.0%
Nov 13Leerink PartnersBuy, reiterated$175+56.8%
Nov 13Canaccord GenuityBuy, reiterated$150+34.4%
Nov 13TD CowenBuy, maintained$137+22.8%
+6.6%average 20-day move after past Accumulation readings
+6.3%average move over the next 20 trading days in the last 5 years
±16.5%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Twist Bioscience seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Twist Bioscience averaged +6.3% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−24.2%2021−30.4%2022+58.7%2023+21.9%2024+15.6%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−4.1%2 of 5
Next 10 trading days0.0%3 of 5
Next 15 trading days+3.7%3 of 5
Next 20 trading days+6.3%3 of 5
Next 30 trading days+10.6%3 of 5

For scale, TWST’s typical 20-trading-day move in either direction is about 15.1%.

Twist Bioscience market cap and key statistics

Twist Bioscience’s market cap is $7.35B and revenue of $431.8M over the last twelve months.

Valuation

Market cap
$7.35B
EPS, TTM
−$2.23
Gekko Fair Value
$131.34

Trading

Volume
2.05M
Avg volume, 20 days
2.41M
52-week high
$219.71
52-week low
$23.30
Shares outstanding
66.30M

Financials

Revenue, TTM
$431.8M
Profit margin
-31.7%
Return on equity
-29.6%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
2.22
Typical daily move
±16.5%
Typical 20-day move
±15.1%

Twist Bioscience stock news this week

Coverage of Twist Bioscience this week reads neutral: 2 positive, 5 neutral and 4 negative headlines.

News sentiment neutral

Twist Bioscience peers

Twist Bioscience’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

Twist Bioscience stock FAQ

What is Twist Bioscience’s market cap?

Twist Bioscience’s market cap is $7.35B at the Nov 13, 2026 close of $111.60, with 66.30M shares outstanding.

What is the Twist Bioscience stock forecast?

The consensus analyst 12-month price target for Twist Bioscience is $168.25, +50.8% from the last close. Of the 9 firms that rated the stock in the last 90 days, 6 rate it a buy, 2 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.

Is Twist Bioscience stock overvalued or undervalued?

On Gekko’s estimate Twist Bioscience is undervalued: the Nov 13, 2026 close of $111.60 is 15.0% below Gekko Fair Value of $131.34. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Twist Bioscience report earnings next?

Twist Bioscience is expected to report on Feb 1, 2027, before the market opens (78 days away). Analysts expect earnings of −$0.39 per share on revenue of $130.9M. Twist Bioscience beat the earnings estimate in 4 of its last 8 reports, moving 10.4% on average across the report.

What is Twist Bioscience’s 52-week high and low?

Twist Bioscience’s 52-week high is $219.71 and its 52-week low is $23.30; it closed at $111.60 on Nov 13, 2026, +250.2% over the past year.

Is Twist Bioscience stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (gekkoindex, fair value, smart money, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Twist Bioscience?

Gekko flagged 1 unusual options signal in Twist Bioscience over the last 30 days, with $1.37M of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Nov 10, 2026 with $1.37M in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Twist Bioscience the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.